Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in REM Sleep Behavior Disorder (PRISMS)
NCT06996652Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Aug 2026
- Primary completion
- Aug 2029
- Countries
- 2
01
Overview
A Phase 2 trial of adalimumab in REM sleep behavior disorder (RBD), sponsored by Yale University. Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
REM sleep behavior disorder (RBD)
Beyond the preview
Go deeper on NCT06996652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06996652.